On October 12, EVEREST MED rose 8.11% in regular trading, trading at HK$32.02 with Turnover of HK$52.30 million. The movement follows the company's announcement of appointing two former Moderna scientists to senior roles, aimed at accelerating its global mRNA strategy.

According to the announcement, Lakshmi Srinivasan was named Senior Vice President and Head of Translational Medicine, while Brandon Coder was appointed Vice President of Translational Sciences and Early Research. The new executives will focus on advancing the mRNA technology platform's clinical development in the United States and related business expansion, collaborating closely with the China R&D team to further upgrade the platform. The appointments underscore EVEREST MED's commitment to strengthening global R&D capabilities and international partnerships, with the board chairman highlighting the addition of top-tier talent as a key step in advancing the company's proprietary mRNA platform and product pipeline globally.

EVEREST MED is a biopharmaceutical company engaged in the R&D, clinical development, manufacturing, and commercialization of innovative drugs and vaccines, with a pipeline spanning nephrology, anti-infectives, and autoimmune diseases. Its commercial products include TARPEYO for nephropathy and eravacycline for multi-drug resistant infections.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)